The US FDA issued a complete response letter for the P2X3 receptor antagonist for the treatment of refractory chronic cough, requesting more efficacy data.

News and highlights of applications submitted for US FDA approval, from the Pink Sheet’s FDA Performance Tracker

New data puts Merck & Co's P2X3 receptor antagonist ahead of the field but Bellus Health's rival in the class may benefit from issues over taste alteration with gefapixant.

Suzhou-based immuno-oncology specialist CStone raised a $260m Series B round and Brii launched with $260m in Series A cash to develop drugs for the China market. Also, multiple start-ups launched recently with more than $50m in Series A rounds, including Ansun, Beam, Casma, Celsius and Neurana.